Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back

Mike Putman, MD, MSc

The Medical College of Wisconsin
Milwaukee, WI, United States

Mike Putman is an Assistant Professor of Medicine at the Medical College of Wisconsin, where he is the Medical Director of the Vasculitis Program and maintains an active practice in general rheumatology. He is involved in education and currently serves as the Associate Program Director for Rheumatology and an Associate Program Director for Internal Medicine. His research interests include clinical trials in vasculitis and myositis, real world evidence, and meta-research. He is also an Associate Editor of the journal Rheumatology and hosts the Evidence Based Rheumatology podcast.

Presentation(s):

  • Keeping Up with Medical Literature

    Friday, November 10, 2023
    3:45 PM – 4:05 PM PT

    Disclosure(s): AbbVie/Abbott: Trial participation (Terminated, January 1, 2023); AstraZeneca: Trial participation (Ongoing); Novartis: Consultant (Terminated, November 10, 2022)

  • Keeping Up with Medical Literature

    Friday, November 10, 2023
    4:05 PM – 4:25 PM PT

    Disclosure(s): AbbVie/Abbott: Trial participation (Terminated, January 1, 2023); AstraZeneca: Trial participation (Ongoing); Novartis: Consultant (Terminated, November 10, 2022)

  • Keeping Up with Medical Literature

    Friday, November 10, 2023
    4:25 PM – 4:45 PM PT

    Disclosure(s): AbbVie/Abbott: Trial participation (Terminated, January 1, 2023); AstraZeneca: Trial participation (Ongoing); Novartis: Consultant (Terminated, November 10, 2022)

  • Keeping Up with Medical Literature

    Friday, November 10, 2023
    4:45 PM – 5:05 PM PT

    Disclosure(s): AbbVie/Abbott: Trial participation (Terminated, January 1, 2023); AstraZeneca: Trial participation (Ongoing); Novartis: Consultant (Terminated, November 10, 2022)

  • Keeping Up with Medical Literature

    Friday, November 10, 2023
    5:05 PM – 5:25 PM PT

    Disclosure(s): AbbVie/Abbott: Trial participation (Terminated, January 1, 2023); AstraZeneca: Trial participation (Ongoing); Novartis: Consultant (Terminated, November 10, 2022)

  • 0480: Non-random Sampling in Rheumatology Randomized Controlled Trials: Evidence of Concerning Trial Conduct?

    Sunday, November 12, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie/Abbott: Trial participation (Terminated, January 1, 2023); AstraZeneca: Trial participation (Ongoing); Novartis: Consultant (Terminated, November 10, 2022)

  • 12S133: Knowledge Bowl Preliminary Round

    Sunday, November 12, 2023
    1:00 PM – 3:00 PM PT

    Disclosure(s): AbbVie/Abbott: Trial participation (Terminated, January 1, 2023); AstraZeneca: Trial participation (Ongoing); Novartis: Consultant (Terminated, November 10, 2022)

  • 13M112: Going Viral: How to Achieve Podcast Success

    Monday, November 13, 2023
    8:30 AM – 9:30 AM PT

    Disclosure(s): AbbVie/Abbott: Trial participation (Terminated, January 1, 2023); AstraZeneca: Trial participation (Ongoing); Novartis: Consultant (Terminated, November 10, 2022)

  • Introduction

    Monday, November 13, 2023
    8:30 AM – 8:35 AM PT

    Disclosure(s): AbbVie/Abbott: Trial participation (Terminated, January 1, 2023); AstraZeneca: Trial participation (Ongoing); Novartis: Consultant (Terminated, November 10, 2022)

  • 1073: Risk of Inflammatory Central Nervous System Diseases Among New Users of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs

    Monday, November 13, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie/Abbott: Trial participation (Terminated, January 1, 2023); AstraZeneca: Trial participation (Ongoing); Novartis: Consultant (Terminated, November 10, 2022)

  • 13M135: Knowledge Bowl Final Round

    Monday, November 13, 2023
    1:00 PM – 3:00 PM PT

    Disclosure(s): AbbVie/Abbott: Trial participation (Terminated, January 1, 2023); AstraZeneca: Trial participation (Ongoing); Novartis: Consultant (Terminated, November 10, 2022)